In summary, our findings demonstrate that DNMT1/FOXO3a/FOXM1/SOX2 signaling promotes BCSC properties, which might contribute to tumor initiation and progression in breast cancer, and that targeting this signaling is a potential therapeutic strategy for breast cancer. This evidence concerns the gene FOXO3 and breast cancer.